A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...

Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may ...

A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the ...

A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as ...

Samsung Biologics has so far secured at least five major contracts this year, and its latest with an unnamed Asia-based ...